Small Cap Feast
Small Cap Feast – 9th February 2017
Dish of the Day:
No AIM Joiners Today
No AIM Joiners Today
Off the Menu:
No AIM Leavers Today
No AIM Leavers Today
What’s Cooking in the IPO Kitchen?
GBGI—Schedule One from the integrated provider of international benefits insurance focused on providing tailored insurance products. Looking to raise £32m with admission expected 22 Feb.
Arix Bioscience — Intention to float on the main market from the global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management
Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
InnovaDerma* (IDP.L) 147.5p £17.47m
Strong growth in today’s HYDec16 interims. Revenue up 125.5% to £3.187m. Gross profit increased significantly by 131% to £1.837m. Underlying trading profit of £0.129m against a comparable period of £0.009m before one-off costs of £287k associated with strategic activity initiatives and corporate activity. Very strong start to H2 with January 2017 delivering the highest ever monthly sales in what is considered to be the slowest month in the self-tanning industry. Opening order for the Professional Salon Range of Skinny Tan in the US through Artisan Tan was achieved in January. New range focused on Mass Market to be launched in 2017 as well as new haircare products. Revenue and profit growth expected in H2. FYJun17E rev of £6.95m and £0.7m PBT.
Proteome Sciences (PRM.L) 4.9p £14.4m
FYDec16 trading update from the specialist in in applied proteomics. “After a strong first half, progress continued throughout the rest of the year with results in line with expectations. Buoyed by robust sales of our TMT® reagents and the associated royalties, unaudited revenues during the full year increased by 46% to approximately £2.74m (2015: £1.88m). Costs and margins were as expected and the Company recorded a loss after tax of approximately £2.30m compared with £2.72m in 2015.“Laboratory consolidation to complete in H1 and relocating head office. Material cost savings from 2018 onwards. Richard Dennis appointed chief commercial officer formerly of Quanterix and Bioscale.
Northbridge Industrial Services (NBI.L) 122.5p £32.5m
FY Dec 16 trading update. ‘Recent trading has been consistent with our internal forecasts and, consequently, the Group expects the result for 2016 to be broadly in line with management’s expectations.’ Has been impacted by slowdown in oil and gas industry which it services. Cautiously optimistic on a revival in exploration and production following Opec quota and subsequent price rise in oil. FY2016E £23.6m rev and £3.8m Pre-tax loss. FY2017E £26m rev and £1..1m Pre-tax loss.
Water Intelligence (WATR.L) 133p £15.96m
FYDec16 trading update from provider of precision, minimally-invasive leak detection and remediation solutions. The Company’s strong financial performance referred to in the Q3 Trading Update on 21 December 2016, continued for the remainder of 2016. Revenue growth exceeded market expectations within all sales channels, including newly acquired UK-based NRW Utilities, with total revenues for the year of $12.2m. (2015: $8.8m) with adjusted profit before tax in-line with market expectations. The Company incurred upfront investment costs that will drive future profitability, as well as significant one-time costs. Margins are expected to grow during 2017 with a full year of trading from the 2016 acquisitions, together with continued organic growth.
CyanConnode Holdings (CYAN.L) 0.21p £33.58m
The specialist in narrowband radio mesh networks, announced the receipt of a purchase order from a specialist in energy management systems for a smart metering contract in Bangladesh, South Asia. This is the Company’s first order for a utility customer in Bangladesh and is a further demonstration of the Company’s growing geographical sales footprint. The $5.4 million purchase order is for the supply of CyanConnode’s Advanced Metering Infrastructure solution for a 150,000 unit smart metering deployment. There are no forecasts in the market.
Faron Pharma (FARN.L) 350p £92.1m
Update from the clinical stage biopharmaceutical Company. At the end of 2016, Faron had approximately €11.5 million in cash. 2017 targets include: read-out for the pan-European phase III trial (INTEREST) results (all-cause mortality at day 28) during H2 2017; Subject to a positive outcome of the INTEREST study, having manufacturing in place should facilitate the application process for market approval of Traumakine®; The Company plans to commence a Phase II US safety study (INTRUST) with Traumakine® in H2 2017. Pre-IND expected in Q3; The Company expects to file the first clinical trial application (CTA) with the UK regulatory authorities (MHRA) in late 2017 / early 2018.
SCISYS (SSY.L) 108p £31.34m
The supplier of bespoke software systems, IT-based solutions and support services to the media, broadcast, space, government, defence and commercial sectors, has signed a contract for up to €1.9m with GMV, a technological business group with an international presence, for the design and implementation of a mission control system to support the EUMETSAT Polar System earth-observation programme. This relates to the 2nd generation of polar-orbiting satellites that will provide weather-prediction data for national meteorological services during the 2020’s & 2030’s. Commencing in 2017, the contract is expected to be delivered by 2021 underpinning current market guidance.
NetScientific (NSCI.L) 60p £30.65m
The transatlantic healthcare IP commercialisation Group, reported that the Chief Scientific Officer of its portfolio company, Vortex Biosciences, Elodie Sollier, has been selected as a finalist for a 2017 SLAS Innovation Award. Elodie, who is one of nine finalists, gave a presentation to the judges on Monday 6 February: “Vortex Technology for fast and label-free isolation of circulating tumour cells from blood samples” where she discussed a breakthrough by Vortex in the isolation of circulating tumour cells from blood samples. Her presentation will be considered by the judges in determining the winner of the award.
Wishbone Gold (WSBN.L) 0.75p £8.5m
Trading update. The precious metals trading Company entered into a debt facility in June 2016 to support its gold trading, with shipments commencing in August 2016. Peak trading was in December 2016 with 105 kilos committed and sold during the month. The Company achieved its target of exceeding 25 kilos per week by the year end. Margins have been under pressure due to India’s change in import rules which provides a premium for gold shipped to, and processed in, certain economic zones. ‘The gold market remains extremely strong in volume terms which makes us believe that the oft quoted decline in production is failing to monitor the small producers which is our target supplier market.’
Asiamet Resources (ARS.L) 4.1p £29.1m
Resource evaluation drilling as part of feasibility studies on the Beruang Kanan Main (“BKM”) copper deposit in Central Kalimantan, Indonesia continues to confirm excellent continuity of high grade copper mineralisation in the BK044 Zone. 10 holes reported today with 48 to go. Results include BKM32550-08 4.35 meters at 4.93% Cu (from 3.00 meters) including 2.0 meters at 8.97% Cu (from 4.0 meters) and 26.85 meters at 2.34% Cu (from 34.15 meters). Feasibility study activities are being progressed at pace on all fronts and several corporate initiatives aimed at further strengthening the Company and providing funding options for the development of BKM have been significantly advanced.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.